Seegene Inc
KOSDAQ:096530
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20 000
34 450
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Seegene Inc
Capital Expenditures
Seegene Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Seegene Inc
KOSDAQ:096530
|
Capital Expenditures
-₩37.9B
|
CAGR 3-Years
18%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
-19%
|
|
|
Celltrion Inc
KRX:068270
|
Capital Expenditures
-₩350.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-13%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Capital Expenditures
-₩50.3B
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Capital Expenditures
-₩29.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Capital Expenditures
-₩27.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Capital Expenditures
-₩32.9B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
Seegene Inc
Glance View
Seegene, Inc. engages in the manufacturing and distributing of molecular diagnostics and reagents. The company is headquartered in Seoul, Seoul. The company went IPO on 2010-09-10. The firm mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases pathogens, human papilloma virus (HPV) and other inspection products, drug resistance inspection products, single nucleotide polymorphisms (SNP) inspection products, as well as somatic mutation cancer inspection products. In addition, it is involved in the provision of automatic real-time detection instruments. The firm provides its products under the brand names of Seeplex, Anyplex and Magicplex. The firm distributes its products within domestic market and to overseas markets.
See Also
What is Seegene Inc's Capital Expenditures?
Capital Expenditures
-37.9B
KRW
Based on the financial report for Sep 30, 2024, Seegene Inc's Capital Expenditures amounts to -37.9B KRW.
What is Seegene Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-19%
Over the last year, the Capital Expenditures growth was -4%. The average annual Capital Expenditures growth rates for Seegene Inc have been 18% over the past three years , -58% over the past five years , and -19% over the past ten years .
You don't have any saved screeners yet
